ClinicalTrials.gg
Enrolling by invitationNCT07156578Updated Feb 10, 2026

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

A Phase 2 interventional study of Bivamelagon in Hypothalamic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Enrolling by invitation at 9 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Sexual Infantilism with a site in United States — 3 open to participants now, 6 under way, 2 of them phase 3. Sexual Infantilism · United States.

Planned enrollment
8th of 14
25 · median 27
Started
2025
with 3 others
Phase 2
7 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
7 of 14
Rhythm Pharmaceuticals, Inc.

Among the 14 studies in Sexual Infantilism with a site in United States, this one is the 8th largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, and was the 14th registered.

Sexual Infantilism

23 studies on the registry are indexed under Sexual Infantilism; 5 are open to participants now.

Browse Sexual Infantilism studies →

Open to participants now

3 of the 14 studies in Sexual Infantilism with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Sexual Infantilism studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sexual Infantilism with a site in United States, or all of them as a file.
02

Study summary

This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.

03

Conditions studied

  • Hypothalamic Obesity

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed LG-MCCL005 and participant demonstrated adequate safety and tolerability in that study as determined by the Investigator.
  • Agree to use a highly effective form of and follow contraception requirements throughout the study and for 90 days after.

Key Exclusion Criteria:

  • Willing to remain off of: inhibitors, strong CYP3A4 inducers, and P-glycoprotein inhibitors or substrates for the duration of the study.
  • In the opinion of the Investigator, participant is not suitable to participate in the study.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Bivamelagon (open-label)

    Drug: Bivamelagon

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of bivamelagon as assessed by the number and frequency of AEs

    Time frame: Baseline to up to 2 years

Secondary outcomes

  1. Mean change and mean percentage change from Baseline in BMI in participants ≥18 years of age.

    Time frame: Baseline to up to 2 years

  2. Mean change in BMI z-score in participants >18 years of age.

    Time frame: Baseline to up to 2 years

  3. Mean change in and mean percentage change in weight

    Time frame: Baseline to up to 2 years

  4. Mean change in percentage of the 95th percentile of BMI in participants <18 years of age.

    Time frame: Baseline to up to 2 years

  5. Percentage of patients who achieve ≥5%,≥10%, ≥15%, and ≥20% reduction in BMI from baseline

    Time frame: Baseline to up to 2 years

  6. Mean change from Baseline in Physical function (and total score) for the Impact of Weight on Quality of Life-Lite (IWQoL) in participants ≥18 years of age

    Time frame: Baseline to up to 2 years

  7. Change from Baseline in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides

    Time frame: Baseline to up 2 years

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Apr 2028, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Sep 5, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Apr 15, 2028
CompletionEst.
Apr 15, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07156578
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Nov 10, 2025
Primary completion
Apr 15, 2028 (estimated)
Completion
Apr 15, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bivamelagon

Start the discussion